Clinical trials: sponsored by Centre for Addiction and Mental Health
Obsessive-Compulsive Disorder
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- PAP-OCD (NCT06299319)
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis
Group Dialectical Behaviour Therapy (DBT) Skills Training for First Episode Psychosis
Psychosis is a serious mental health condition that can affect how a person thinks, feels, and functions in daily life, often making it harder to maintain relationships, continue education, or work.
- Trial name
- NCT07777315
- Testing
- group DBT
- Volunteers
- 32 people
- Sponsor
- Centre for Addiction and Mental Health
Clinical High Risk for Psychosis (CHR)
Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis
This study examines the feasibility and acceptability of a digital dialectical behavior therapy (d-DBT) intervention for youth at clinical high risk (CHR) for psychosis.
- Trial name
- NCT06928935
- Testing
- d-DBT
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective
Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia
This study will examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia.
- Trial name
- NCT05435300
- Testing
- PET Scan
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Centre for Addiction and Mental Health
Depression / Major Depressive Disorder, Bipolar Disorder (BD)
Identifying Biomarkers of Response to Digital Interventions for Mood Disorders
The proposed study will be a single-arm pragmatic clinical trial examining the feasibility of online CBT within the CAN-BIND sites and the biomarkers of treatment response to online CBT for mood disorders.
- Trial name
- CAN-BIND-iCBT (NCT07783633)
- Testing
- Online Cognitive Behavioural Therapy
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia;Schizoaffective
The Effects of Non-invasive Brain Stimulation on Treatment Adherence in Schizophrenia
This study seeks to explore the effects of transcranial direct current stimulation (tDCS), a non-invasive method of brain stimulation, as an adjunctive treatment to improve antipsychotic medication adherence in patients with…
- Trial name
- NCT04033679
- Testing
- Active TDCS
- Where
- Canada
- Volunteers
- 106 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics; for example, it is recommended that agents with a short plasma half-life be administered multiple times per day.
- Trial name
- NCT02639702
- Testing
- Clozapine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment-Resistant Depression
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- PSI-TNT (NCT07211438)
- Testing
- Psilocybin
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
Effectiveness of an Integrated Care Pathway for Depression: Cluster Randomized Controlled Trial
This is a quasi-experimental, multi-site cluster controlled clinical trial design with two intervention arms--Treatment As Usual (TAU) and an Integrated Care Pathway (ICP).
- Trial name
- CARIBOU-2 (NCT05142683)
- Testing
- Treatment As Usual, CARIBOU-2
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Psychomotor Impairment
Combined Alcohol and Cannabis Effects on Skills of Young Drivers
Alcohol and cannabis are the two most widely used substances of abuse in the world and are the psychoactive substances most often found in seriously and fatally injured drivers.
- Trial name
- NCT03106363
- Testing
- alcohol, delta 9 tetrahydrocannabinol
- Where
- Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Mental Health Disorder, Aging
Community-based Cognitive Remediation and tDCS to Enhance Seniors' Function and Mental Health
Focusing on seniors with mental health conditions who are living in the community, this initiative proposes to assess the acute and long-term effects of an 8-week course of daily (5 days/week) cognitive remediation (CR) training…
- Trial name
- CREAtE (NCT04648371)
- Testing
- Cognitive Remediation and Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Centre for Addiction and Mental Health
Multiple Mental Health Conditions, Child Mental Health
Cohort Network for Adolescents and Youth With multipLe Mental Health Conditions
The Cohort Network for Adolescents and Youth With multipLe Mental Health Conditions (CALM) Master Observational Trial is a prospective, longitudinal observational study that seeks to improve clinical care for youth with multiple…
- Conditions
- Multiple Mental Health Conditions, Child Mental Health, Youth Mental Health
- Trial name
- CALM (NCT07699159)
- Where
- 6 sites in Canada
- Volunteers
- 1,620 people
- Sponsor
- Centre for Addiction and Mental Health
Autism Spectrum Disorder, Motor Activity
rTMS to Improve Motor Function in Autism
In the current project, investigators have two main goals: i) Testing whether an excessive plasticity, i.e. hyperplasticity in the motor cortex underlies motor function difficulties in autistic adults, and ii) Using repetitive…
- Trial name
- (AMBLE Autism) (NCT06497920)
- Testing
- Active rTMS to the motor cortex
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Stress Disorders, Post-Traumatic, Alcohol Use Disorder
Testing a Novel Therapeutic Strategy for Comorbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
This study evaluates the therapeutic tolerability of the use of Cognitive Processing Therapy (CPT) with propranolol in participants with Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD).
- Trial name
- NCT05692271
- Testing
- Propranolol
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Centre for Addiction and Mental Health
THC
THC Titration of High-Potency Cannabis Concentrates
High-potency cannabis use is associated with public health risks, such as cannabis use disorder, psychotic disorders, and impaired cognition.
- Trial name
- THC Titration (NCT07105449)
- Testing
- Cannabis (30% THC Concentrate), Cannabis (60% THC Concentrate), Cannabis (90% THC Concentrate)
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Alcohol Misuse
Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Treatment Seeking Smokers
This study will evaluate the implementation of a fully automated, direct-to-patient digital alcohol intervention embedded within the STOP Program's patient portal.
- Trial name
- NCT07228923
- Testing
- Brief alcohol intervention
- Where
- Canada
- Volunteers
- 77 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Topiramate and Schizophrenia: Effects on Weight and Psychopathology
Clozapine is the sole AP agent with superiority in treatment refractory schizophrenia, but it also is associated with the greatest risk of weight gain and other metabolic abnormalities.
- Trial name
- NCT02808533
- Testing
- Topiramate
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre for Addiction and Mental Health
Psychotic Disorder, Schizophrenia
Gut Microbiome in AP Naive
Antipsychotic (AP) medications are currently the cornerstone of treatment for schizophrenia (SCZ), with off-label prescription rapidly increasing in youth, with an established two-fold increase in standardized mortality ratio…
- Trial name
- NCT03414151
- Testing
- Observation
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia Spectrum Disorders
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
Rates of obesity in patients with schizophrenia-spectrum disorder (SSD)s have reached epidemic proportions, with established contributing effects of antipsychotic (AP) medications.
- Trial name
- Sema (NCT05333003)
- Testing
- Semaglutide
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- Centre for Addiction and Mental Health
Posttraumatic Stress Disorder (PTSD), Substance Use Disorders
Efficacy of an EMDR App for PTSD and SUD
The current proposal is aimed to confirm the efficacy of this novel therapeutic method (autonomous eye movement desensitization and reprocessing; A-EMDR) in a patient group (PTSD and SUD), and to assess the feasibility of the…
- Trial name
- NCT07146633
- Testing
- A-EMDR, Treatment as Usual (TAU)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre for Addiction and Mental Health